Cornerstone Therapeutics, Inc. (CRTX) Tops Q2 EPS by 5c, Revenues Beat Expectations
Tweet
Share
E-mailGet Alerts CRTX Hot Sheet
Price: $1.95 --0%
Financial Fact:
Net income (loss) per share, diluted: 0.31
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net income (loss) per share, diluted: 0.31
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) reported Q2 adjusted EPS of $0.11, $0.05 better than the analyst estimate of $0.06. Revenue for the quarter came in at $28.04 million versus the consensus estimate of $25.71 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Omega Flex (OFLX) Tops Q2 EPS by 27c
- CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
